× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Background

What do we already know about this topic?

  • The majority of patients with IIH continue to have headaches after their cerebrospinal fluid (CSF) pressure has normalized.1,2
  • Currently, there is no standard protocol for treating patients with post-IIH headache.
  • A large proportion of patients with IIH have a history of migraine; therefore, treatment with an anti-CGRP mAb may improve headache frequency, severity, and disability in patients with persistent headaches following treatment for IIH.3

How was this study conducted?

  • A retrospective chart review study of 24 patients with IIH who had previously undergone or are undergoing treated with an anti-CGRP mAb for the treatment of post-IIH headache between May 1, 2018, to January 1, 2020.
  • The primary outcome measure was change in mean headache days per month compared to baseline.